Royalty Pharma(RPRX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 LTY PHARMA ROYALTY PHARMA REPORTS SECOND QUARTER 2024 RESULTS • Portfolio Receipts growth of 12% to $608 million; Royalty Receipts growth of 11% • Net cash provided by operating activities of $658 million • Raising full year 2024 guidance: Portfolio Receipts expected to be $2,700 to $2,775 million NEW YORK, NY, August 8, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts. "We delivere ...